HC Wainwright Issues Optimistic Outlook for CNTX Earnings

Key Points

• HC Wainwright raised its earnings estimates for Context Therapeutics, lifting its Q2 2026 EPS forecast to -$0.10 from -$0.15 and increasing projections for 2026 through 2029.
• Context Therapeutics beat expectations in its latest quarter, reporting EPS of -$0.09 versus the consensus estimate of -$0.12.
• Analyst sentiment remains favorable overall, with the stock holding a Moderate Buy consensus and an average target price of $6.60, though the company is still expected to remain unprofitable in coming years.

Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Stock analysts at HC Wainwright upped their Q2 2026 earnings estimates for Context Therapeutics in a research note issued on Thursday, May 7th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($0.10) for the quarter, up from their prior forecast of ($0.15). The consensus estimate for Context Therapeutics' current full-year earnings is ($0.35) per share. HC Wainwright also issued estimates for Context Therapeutics' Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.43) EPS, FY2027 earnings at ($0.45) EPS, FY2028 earnings at ($0.44) EPS and FY2029 earnings at ($0.27) EPS.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.03.

Several other research firms have also weighed in on CNTX. Wall Street Zen upgraded shares of Context Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. Guggenheim restated a "buy" rating and set a $5.00 price objective on shares of Context Therapeutics in a research note on Tuesday, March 24th. Lifesci Capital upgraded shares of Context Therapeutics to a "strong-buy" rating in a research note on Monday, February 23rd. Piper Sandler boosted their price objective on shares of Context Therapeutics from $4.00 to $7.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 24th. Finally, D. Boral Capital restated a "buy" rating and set a $9.00 price objective on shares of Context Therapeutics in a research note on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Context Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $6.60.

Context Therapeutics Price Performance

Context Therapeutics stock opened at $2.38 on Monday. The firm has a market capitalization of $218.67 million, a PE ratio of -5.67 and a beta of 1.57. The company's 50-day moving average is $2.62 and its 200-day moving average is $1.90. Context Therapeutics has a fifty-two week low of $0.49 and a fifty-two week high of $3.62.

Institutional Trading of Context Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Blue Owl Capital Holdings LP boosted its holdings in shares of Context Therapeutics by 0.3% during the 4th quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company's stock worth $10,926,000 after buying an additional 25,000 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Context Therapeutics by 4.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company's stock worth $3,387,000 after buying an additional 134,449 shares during the period. Millennium Management LLC bought a new stake in shares of Context Therapeutics during the 4th quarter worth about $3,824,000. Marshall Wace LLP boosted its holdings in shares of Context Therapeutics by 7,153.7% during the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company's stock worth $3,812,000 after buying an additional 2,557,448 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in shares of Context Therapeutics by 58.8% during the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company's stock worth $747,000 after buying an additional 188,202 shares during the period. Institutional investors own 14.03% of the company's stock.

Context Therapeutics News Summary

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Lifesci Capital raised its 2026 EPS estimates and maintained a Strong-Buy rating, suggesting improved expectations for Context Therapeutics’ near-term financial performance.
• Positive Sentiment: HC Wainwright also increased EPS forecasts for 2026 through 2029, indicating analysts see a better long-term earnings path for Context Therapeutics.
• Neutral Sentiment: Despite the upgrades, the company is still expected to report losses in each forecast period, so the revisions reflect reduced losses rather than a move to profitability.

About Context Therapeutics

Context Therapeutics NASDAQ: CNTX is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company's research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.